UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 61 - 75 of 671

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Sacral nerve stimulation for refractory overactive bladder in the elderly population - Abstract
Tuesday, 01 September 2009
Division of Urologic Surgery, University of Tennessee Medical Center, Knoxville, Tennessee.
read more

Comparison of photoselective vaporization and standard transurethral resection of the prostate on urodynamics in patients with benign prostatic hyperplasia - Abstract
Monday, 31 August 2009
Division of Urology, Harasanshin Hospital, Kyushu University, Higashi-ku, Fukuoka, Japan.
read more

Tolterodine extended-release for overactive bladder - Abstract
Monday, 31 August 2009
Weill Cornell Medical College, Department of Urology, 1300 York Avenue, Box 261, Suite F9 West, New York, NY 10065, USA.
read more

Sleep apnea in urology : Influence of obstructive sleep apnea on erection and bladder function - Abstract
Friday, 28 August 2009
Erasmus Medical Center, s-Gravendijkwal 230, NL-3015, CE Rotterdam, Niederlande.
read more

Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study - Abstract
Friday, 28 August 2009
Department of Urology, Mayo Clinic, Jacksonville, FL 32224, USA.
read more

Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children - Abstract
Friday, 28 August 2009
Urodynamic Unit, Department of Nephrology-Urology, Children's Hospital "Bambino Gesù," Rome, Italy.
read more

Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study - Abstract
Thursday, 27 August 2009
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
read more

24-Hour rectal manometry for overactive bladder - Abstract
Thursday, 27 August 2009
Institute of Clinical Medicine, University of Aarhus, Aarhus, Denmark.
read more

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release - Abstract
Wednesday, 26 August 2009
Department of Urology, William Beaumont Hospital, Detroit, Michigan.
read more

Patient Guide - Controlling Your Bladder Symptoms
Tuesday, 25 August 2009
Login to read more...

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder - Abstract
Tuesday, 25 August 2009
Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, USA.
read more

URS 2009 - Effects of a novel peripheral selective cannabinoid-2-receptor agonist (Cannabinor) on bladder function in normal rats and rats with partial urethral obstruction - Abstract
Monday, 24 August 2009
PORT DOUGLAS, AUSTRALIA (UroToday.com) - The aim of the current study was to characterize the distribution of the cannabinoid-2-receptor (CB2) in the rat bladder and to study effects of Cannabinor, a peripherally acting selective CB2 agonist, on isolated rat detrusor and on bladder function during cystometry in normal rats and rats with partial urethral obstruction.
Login to read more...

URS 2009 - Urothelium-derived inhibitory factors and the human neurogenic overactive bladder - Abstract
Monday, 24 August 2009
PORT DOUGLAS, AUSTRALIA (UroToday.com) - The urothelium (urothelium plus suburothelium) has been shown to release a diffusible factor that inhibits the underlying detrusor smooth muscle.
Login to read more...

URS 2009 - ATP release in response to acid and capsaicin provides evidence for sensory roles of vanilloid and ASIC receptor systems in the rat bladder mucosa - Abstract
Monday, 24 August 2009
PORT DOUGLAS, AUSTRALIA (UroToday.com) - ATP has important sensory and motor functions in the urinary bladder.
Login to read more...

URS 2009 - TRPV4 as a mechanoreceptor in the human bladder: A co-localization between TRPV4 and adherence junctions in the human bladder urothelium - Abstract
Monday, 24 August 2009
PORT DOUGLAS, AUSTRALIA (UroToday.com) - Transient receptor potential vanilloid receptor 4 (TRPV4) is a calcium specific ion-channel that is activated by physical stimuli like ‘stretch.’
Login to read more...

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder